Abstract
Activation of gasdermin D (GSDMD) and its concomitant cardiomyocyte pyroptosis are critically involved in multiple cardiac pathological conditions. Pharmacological inhibition or gene knockout of GSDMD could protect cardiomyocyte from pyroptosis and dysfunction. Thus, seeking and developing highly potent GSDMD inhibitors probably provide an attractive strategy for treating diseases targeting GSDMD. Through structure-based virtual screening, pharmacological screening and subsequent pharmacological validations, we preliminarily identified GSDMD inhibitor Y1 (GI-Y1) as a selective GSDMD inhibitor with cardioprotective effects. Mechanistically, GI-Y1 binds to GSDMD and inhibits lipid- binding and pyroptotic pore formation of GSDMD-N by targeting the Arg7 residue. Importantly, we confirmed the cardioprotective effect of GI-Y1 on myocardial I/R injury and cardiac remodeling by targeting GSDMD. More extensively, GI-Y1 also inhibited the mitochondrial binding of GSDMD-N and its concomitant mitochondrial dysfunction. The findings of this study identified a new drug (GI-Y1) for the treatment of cardiac disorders by targeting GSDMD, and provide a new tool compound for pyroptosis research.
Similar content being viewed by others
Data availability
All the data in this study are available upon reasonable request from the corresponding author.
References
Chen Y, Luo R, Li J, Wang S, Ding J, Zhao K, Lu B, Zhou W (2022) Intrinsic radical species scavenging activities of tea polyphenols nanoparticles block pyroptosis in endotoxin-induced sepsis. ACS Nano 16:2429–2441. https://doi.org/10.1021/acsnano.1c08913
Dai S, Ye B, Zhong L, Chen Y, Hong G, Zhao G, Su L, Lu Z (2021) GSDMD mediates LPS-induced septic myocardial dysfunction by regulating ROS-dependent NLRP3 inflammasome activation. Front Cell Develop Biol 9:779432. https://doi.org/10.3389/fcell.2021.779432
Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN (2019) Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev 99:1765–1817. https://doi.org/10.1152/physrev.00022.2018
Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ (2013) Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 34:1714–1722. https://doi.org/10.1093/eurheartj/eht090
Han B, Xu J, Shi X, Zheng Z, Shi F, Jiang F, Han J (2021) DL-3-n-butylphthalide attenuates myocardial hypertrophy by targeting gasdermin D and inhibiting gasdermin D mediated inflammation. Front Pharmacol 12:688140. https://doi.org/10.3389/fphar.2021.688140
Han J, Dai S, Zhong L, Shi X, Fan X, Zhong X, Lin W, Su L, Lin S, Han B, Xu J, Hong X, Huang W, Ye B (2022) GSDMD (gasdermin D) mediates pathological cardiac hypertrophy and generates a feed-forward amplification Cascade via mitochondria-STING (stimulator of interferon genes) Axis. Hypertension 79:2505–2518. https://doi.org/10.1161/hypertensionaha.122.20004
Han J, Shi X, Xu J, Lin W, Chen Y, Han B, Wang Y, Xu J (2022) DL-3-n-butylphthalide prevents oxidative stress and atherosclerosis by targeting Keap-1 and inhibiting Keap-1/Nrf-2 interaction. Eur J Pharmaceut Sci 172:106164. https://doi.org/10.1016/j.ejps.2022.106164
Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Kloner RA, Ovize M, Yellon DM, Garcia-Dorado D (2017) Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 38:935–941. https://doi.org/10.1093/eurheartj/ehw145
Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17:773–789. https://doi.org/10.1038/s41569-020-0403-y
Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, Wang J, Hollingsworth LR, Magupalli VG, Zhao L, Luo HR, Kim J, Lieberman J, Wu H (2020) FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol 21:736–745. https://doi.org/10.1038/s41590-020-0669-6
Huang LS, Hong Z, Wu W, Xiong S, Zhong M, Gao X, Rehman J, Malik AB (2020) mtDNA activates cGAS signaling and suppresses the YAP-mediated endothelial cell proliferation program to promote inflammatory injury. Immunity 52(475–486):e475. https://doi.org/10.1016/j.immuni.2020.02.002
Ibáñez B, Heusch G, Ovize M, Van de Werf F (2015) Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 65:1454–1471. https://doi.org/10.1016/j.jacc.2015.02.032
Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discovery 3:935–949. https://doi.org/10.1038/nrd1549
Kuang S, Zheng J, Yang H, Li S, Duan S, Shen Y, Ji C, Gan J, Xu XW, Li J (2017) Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis. Proc Natl Acad Sci USA 114:10642
Lesnefsky EJ, Chen Q, Tandler B, Hoppel CL (2017) Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies. Annu Rev Pharmacol Toxicol 57:535–565. https://doi.org/10.1146/annurev-pharmtox-010715-103335
Li Y, Shen J, Fang M, Huang X, Yan H, Jin Y, Li J, Li X (2018) The promising antitumour drug disulfiram inhibits viability and induces apoptosis in cardiomyocytes. Biomed Pharmacother Biomed Pharmacother 108:1062–1069. https://doi.org/10.1016/j.biopha.2018.09.123
Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J (2016) Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535:153
Liu Z, Wang C, Yang J, Zhou B, Yang R, Ramachandran R, Abbott DW, Xiao TS (2019) Crystal structures of the full-length murine and human gasdermin D reveal mechanisms of autoinhibition, lipid binding, and oligomerization. Immunity 51:43-49.e44. https://doi.org/10.1016/j.immuni.2019.04.017
Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, Wang J, Wu RP, Gomez F, Loo JA, Wohlschlegel JA, Vondriska TM, Pelletier J, Herschman HR, Clardy J, Clarke CF, Huang J (2009) Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA 106:21984–21989. https://doi.org/10.1073/pnas.0910040106
Mali VR, Deshpande M, Pan G, Thandavarayan RA, Palaniyandi SS (2016) Impaired ALDH2 activity decreases the mitochondrial respiration in H9C2 cardiomyocytes. Cell Signal 28:1–6. https://doi.org/10.1016/j.cellsig.2015.11.006
Nobuhiko K, Stowe IB, Lee BL, Karen OR, Keith A, Søren W, Trinna C, Benjamin H, Merone RG, Phung QT (2015) Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526:666–671
Pan G, Deshpande M, Thandavarayan RA (2016) ALDH2 inhibition potentiates high glucose stress-induced injury in cultured cardiomyocytes. J Diabetes Res 2016:1390861
Platnich JM, Chung H, Lau A, Sandall CF, Bondzi-Simpson A, Chen HM, Komada T, Trotman-Grant AC, Brandelli JR, Chun J, Beck PL, Philpott DJ, Girardin SE, Ho M, Johnson RP, MacDonald JA, Armstrong GD, Muruve DA (2018) Shiga toxin/lipopolysaccharide activates Caspase-4 and gasdermin D to trigger mitochondrial reactive oxygen species upstream of the NLRP3 inflammasome. Cell Rep 25:1525-1536.e1527. https://doi.org/10.1016/j.celrep.2018.09.071
Rathkey JK, Zhao J, Liu Z, Chen Y (2018) Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol. https://doi.org/10.1126/sciimmunol.aat2738
Ren YS, Li HL, Piao XH, Yang ZY, Wang SM, Ge YW (2021) Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: principles and application. Biochem Pharmacol 194:114798. https://doi.org/10.1016/j.bcp.2021.114798
Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES (2019) Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun 10:1689. https://doi.org/10.1038/s41467-019-09397-2
Ruan J, Xia S, Liu X, Lieberman J, Wu H (2018) Cryo-EM structure of the gasdermin A3 membrane pore. Nature 557:62–67. https://doi.org/10.1038/s41586-018-0058-6
Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526:660–665. https://doi.org/10.1038/nature15514
Shi J, Gao W, Shao F (2017) Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 42:245–254. https://doi.org/10.1016/j.tibs.2016.10.004
Shi H, Gao Y, Dong Z, Yang J, Gao R, Li X, Zhang S, Ma L, Sun X, Wang Z, Zhang F, Hu K, Sun A, Ge J (2021) GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury. Circ Res 129:383–396. https://doi.org/10.1161/circresaha.120.318629
Xu J, Zhang B, Chu Z, Jiang F, Han J (2021) Wogonin alleviates cisplatin-induced cardiotoxicity in mice via inhibiting gasdermin D-mediated pyroptosis. J Cardiovasc Pharmacol 78:597–603. https://doi.org/10.1097/fjc.0000000000001085
Yang J, Liu Z, Wang C, Yang R, Rathkey JK, Pinkard OW, Shi W, Chen Y, Dubyak GR, Abbott DW, Xiao TS (2018) Mechanism of gasdermin D recognition by inflammatory caspases and their inhibition by a gasdermin D-derived peptide inhibitor. Proc Natl Acad Sci USA 115:6792–6797. https://doi.org/10.1073/pnas.1800562115
Yang X, Wang Y, Byrne R, Schneider G, Yang S (2019) Concepts of artificial intelligence for computer-assisted drug discovery. Chem Rev 119:10520–10594. https://doi.org/10.1021/acs.chemrev.8b00728
Ye B, Chen X, Dai S, Han J, Liang X, Lin S, Cai X, Huang Z, Huang W (2019) Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes. Drug Des Dev Ther 13:975–990. https://doi.org/10.2147/DDDT.S195412
Ye B, Shi X, Xu J, Dai S, Xu J, Fan X, Han B, Han J (2022) Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage. Transl Res 248:36–50. https://doi.org/10.1016/j.trsl.2022.05.001
Ye X, Zhang P, Zhang Y, Luan J, Xu C, Wu Z, Ju D, Hu W (2022) GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis. Front Immunol 13:893914. https://doi.org/10.3389/fimmu.2022.893914
Yu Q, Jiang Y, Sun Y (2020) Anticancer drug discovery by targeting cullin neddylation. Acta pharmaceutica Sinica B 10:746–765. https://doi.org/10.1016/j.apsb.2019.09.005
Acknowledgements
We appreciate Professor Lufeng Hu from the Department of Pharmacy of First Affiliated Hospital of Wenzhou Medical University for his help in chromatographic analysis. We are grateful to Lingli Hou, Tongliang Huang, Yanni Dong, Jiansong Lin and Mengxin Zhang from the scientific research center of Wenzhou Medical University for their help in echocardiography and immunofluorescence experiment.
Funding
This study was supported by the National Natural Science Foundation of China (No. 82003750 to B.Z. Ye, No. 82202380 to S.S. Dai, No. 82070446 to W.J. Huang), Zhejiang Provincial Natural Science Foundation of China (No. LQ21H020009 to B.Z. Ye, No. LQ23H310005 to S.S. Dai, No. LGD21H020003 to J.B. Han, No. LY22H02004 to Z.Q. Huang), the Key Research and Development Program of Zhejiang (No.2019C03012 to W.J. Huang), Zhejiang Provincial Health Bureau Science Foundation (No. 2022RC046 to S.S. Dai), Wenzhou Science and Technology Bureau (No. Y20220082 to S.S. Dai) and Zhejiang Provincial Science and Technology Innovation Program (New Young Talent Program) for College Students (No. 2022R413C081 to L.F. Zhong).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
All the authors declare no competing financial interest.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhong, L., Han, J., Fan, X. et al. Novel GSDMD inhibitor GI-Y1 protects heart against pyroptosis and ischemia/reperfusion injury by blocking pyroptotic pore formation. Basic Res Cardiol 118, 40 (2023). https://doi.org/10.1007/s00395-023-01010-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00395-023-01010-4